SK Biopharm secures $795M epilepsy drug rights

South Korean company SK Biopharmaceuticals Co. signed a global exclusive licensing agreement with Biohaven Bioscience Ireland Ltd. for the epilepsy drug candidate Opakalim, valued at approximately 1.9...